FBLG•globenewswire•
FibroBiologics to Present at the DealFlow Discovery Conference
Summary
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 20, 2026 by globenewswire